ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen and BCG alone.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The company also confirmed that the supplemental Biologics License Application (BLA) for the therapy is progressing as planned, with a target completion in 2026.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$81,748.16
-1.94%
Ethereum
ETH
$2,399.97
-2.53%
Tether USDt
USDT
$0.9989
+0.02%
BNB
BNB
$733.31
-1.65%
XRP
XRP
$1.33
-2.12%
USDC
USDC
$0.9999
-0.00%
Solana
SOL
$104.5
-2.04%
TRON
TRX
$0.3303
-0.11%
Zcash
ZEC
$1,260.41
-1.85%
Hyperliquid
HYPE
$78.49
-3.34%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now